top of page
News, Events and Updates
Search
Anavex Appoints Senior Healthcare and Pharmaceutical Executives to Board of Directors
May 7, 2014
Anavex Encouraged by Scientific Data; Sigma-1 Receptor Agonist is Potentially Disease-Modifying
Mar 31, 2014
Anavex Strengthens Alzheimer's Pipeline, Obtains Exclusive Worldwide Rights to Intellectual Property
Mar 30, 2014
Anavex Reports Predicted Clinical Effect of Both ANAVEX 2-73 and ANAVEX PLUS
Mar 26, 2014
A novel multipotent sigma 1/M1 muscarinic activator for a comprehensive therapeutic strategy in AD
Mar 25, 2014
Anavex Successfully Closes $10M Financing to Initiate Phase 1b/2a Alzheimer's Clinical Trial
Mar 18, 2014
Anavex Announces $10M Private Placement of Convertible Debentures
Mar 12, 2014
Anavex Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Extends Survival in ALS
Mar 9, 2014
Anavex: Research Report Reveals Cardioprotective Action of Sigma-1 Receptor Agonists
Mar 4, 2014
40
41
42
43
44
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
